

Senate Bill 486 Evaluation Team
CONSUMER REPORT CARD



<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Abbott Laboratories	92	A-
Amgen	62	D-
Amylin	22	F
Baxter	2	F
Bayer	21	F
Biogen Idec	22	F
Bristol Meyers Squibb	75	C
Centocor Ortho Biotech/ Johnson & Johnson	93	A-
CSL Behring	2	F
Eisai	46	F
Eli Lilly	23	F
EMD Serono/Gonal-f	65	D
EMD Serono/ Other	68	C
Ferring	17	F
GlaxoSmithKline	49	F
InterMune	20	F
Merck & Co.	32	F
Pfizer	35	F
Roche/Genentech	73	C
Sanofi-Aventis	36	F
Teva Biologics	18	F
Teva Neuroscience	22	F

SUMMARY:

While the legislatively mandated deadline for report submission was July 1, 2010. There were 22 plans submitted as of July 7th to the State of California which posted them on their website for public consumption on July 27th. These plans were read and graded by a 9-person evaluation team, scoring each plan based on published consumer criteria. There were:

- Two "A" grade plans;
- Three "C" grade plans;
- Two "D" grade plans;
- Fifteen "F" grade plans;
- Twelve "F/Incomplete" grade plans for those manufacturers who did not submit plans by the legislatively mandated deadline of July 1.
- One "Honorable Mention"

HONORABLE MENTION:

Waste Management, Inc.

Although they weren't subject to SB 486, they submitted a plan and earned an **honorable mention** from the SB 486 Evaluation Committee.

The following drug manufactures earned an automatic F grade based on the incomplete nature of their reports. Those manufacturers are:

IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY DID NOT SUBMIT ANY PLANS TO THE STATE.

<u>Manufacturer</u>	<u>Grade</u>
Biovitrium	F/Incomplete
EMD Serono (for their drug Zorbtive only)	F/Incomplete
Hoffmand LaRoche	F/Incomplete
Ipsen/Mylan Bertek	F/Incomplete
Questcor Pharmaceuticals	F/Incomplete
UCD S.A.	F/Incomplete
Zoegenix	F/Incomplete

IN VIOLATION OF STATE LAW DUE TO THE FACT THAT THEY SUBMITTED PLANS TO THE STATE AFTER LEGISLATIVELY MANDATED JULY 1ST DEADLINE.

<u>Manufacturer</u>	<u>Score</u>	<u>Grade</u>
Bayer (submitted July 7)	21	F
Dey (submitted August 18)		F/Incomplete
Merck & Co (Met July 1 st deadline, then rewrote & resubmitted their plan October 21)	32	F
Novartis (submitted September 14)		F/Incomplete
Novo Nordisk (submitted July 28)		F/Incomplete
Shinogi Pharma (submitted August 19)		F/Incomplete
Three Rivers (submitted October 1)		F/Incomplete